3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Gastrointestinal
2
Endocrine
2
Conditions
Breast Neoplasms
20
Carcinoma, Renal Cell
10
Neuroendocrine Tumors
7
Neoplasm Metastasis
7
Recurrence
4
Tuberous Sclerosis
3
Triple Negative Breast Neoplasms
3
Neoplasms
3
Kidney Neoplasms
3
Endometrial Neoplasms
3
von Hippel-Lindau Disease
2
Skin Neoplasms
2
Sarcoma
2
Meningioma
2
Glioma
2
Gastro-enteropancreatic neuroendocrine tumor
2
Diffuse Intrinsic Pontine Glioma
2
Carcinoma, Hepatocellular
2
Adenoma, Islet Cell
2
Waldenstrom Macroglobulinemia
1
Vascular Malformations
1
Unilateral Breast Neoplasms
1
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Thymus Neoplasms
1
Seizures
1
Sarcoma, Kaposi
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Interventions
lutetium Lu 177 dotatate
6
Octreotide
3
pasireotide
2
lanreotide
2
gallium Ga 68 dotatate
2
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
irinotecan sucrosofate
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Radiosurgery
1
PM 01183
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Everolimus
×
1 year
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled